CLINICAL_TRIALS
ClinicalTrials.gov record update
Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03541902
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:40.775969+00:00
- Published At
- 2026-01-09T00:00:00+00:00
- Record Updated At
- 2026-01-09
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Malignant Neoplasms of Urinary Tract", "Renal Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v8", "Unclassified Renal Cell Carcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-09"- protocolSection.identificationModule.nctId
"NCT03541902"- protocolSection.identificationModule.officialTitle
"Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.